<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04960124</url>
  </required_header>
  <id_info>
    <org_study_id>CR108929</org_study_id>
    <secondary_id>2020-005235-69</secondary_id>
    <secondary_id>42847922MDD1012</secondary_id>
    <nct_id>NCT04960124</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants</brief_title>
  <official_title>An Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of JNJ-42847922 in Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of&#xD;
      JNJ-42847922 in adult participants with hepatic impairment when compared to healthy&#xD;
      participants with normal hepatic function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">September 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 13, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Analyte Concentration (Cmax) of JNJ-42847922 and its Metabolites M12 and M16</measure>
    <time_frame>Pre-dose, up to 96 hours post-dose (up to Day 5)</time_frame>
    <description>Cmax is defined as maximum observed plasma analyte concentration of JNJ-42847922 and its metabolites M12 and M16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Plasma Analyte Concentration versus Time Curve from Time Zero to Time of Last Measurable Concentration (AUC [0-last]) of JNJ-42847922 and its Metabolites M12 and M16</measure>
    <time_frame>Pre-dose, up to 96 hours post-dose (up to Day 5)</time_frame>
    <description>AUC(0-last) is defined as area under the plasma analyte concentration versus time curve from time zero to time of last measurable concentration of JNJ-42847922 and its metabolites M12 and M16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Analyte Concentration versus Time Curve from Time Zero to Infinite Time (AUC[0-Infinity]) of JNJ-42847922 and its Metabolites M12 and M16</measure>
    <time_frame>Pre-dose, up to 96 hours post-dose (up to Day 5)</time_frame>
    <description>AUC(0-infinity) is defined as the area under the plasma analyte concentration versus time curve from time zero to infinite time of JNJ-42847922 and its metabolites M12 and M16.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Day 5</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Healthy</condition>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Part 1: Cohort 1 (JNJ-42847922)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with normal hepatic function will receive Dose 1 of JNJ-42847922 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 2 (JNJ-42847922)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment will receive Dose 1 of JNJ-42847922 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 3 (JNJ-42847922)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment will receive Dose 2 of JNJ-42847922 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 4 (Optional) (JNJ-42847922)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment will receive Dose 1 (depending on the results of Cohort 3) of JNJ-42847922 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 5 (Optional) (JNJ-42847922)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe hepatic impairment will receive Dose 2 or Dose 3 (depending on the results of Part 1) of JNJ-42847922 on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-42847922</intervention_name>
    <description>Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.</description>
    <arm_group_label>Part 1: Cohort 1 (JNJ-42847922)</arm_group_label>
    <arm_group_label>Part 1: Cohort 2 (JNJ-42847922)</arm_group_label>
    <arm_group_label>Part 1: Cohort 3 (JNJ-42847922)</arm_group_label>
    <arm_group_label>Part 2: Cohort 4 (Optional) (JNJ-42847922)</arm_group_label>
    <arm_group_label>Part 2: Cohort 5 (Optional) (JNJ-42847922)</arm_group_label>
    <other_name>Seltorexant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All&#xD;
&#xD;
          -  Be a man or woman 18 to 79 years of age, inclusive Participants with normal hepatic&#xD;
             function&#xD;
&#xD;
          -  Generally healthy&#xD;
&#xD;
          -  Must not exceed upper limit of normal limits for serum bilirubin, transaminase levels,&#xD;
             albumin levels, prothrombin time (PT), and International Normalized Ratio (INR) when&#xD;
             measured at screening and Day 1 Participants with (Mild, Moderate or Severe) hepatic&#xD;
             impairment&#xD;
&#xD;
          -  Medically stable&#xD;
&#xD;
          -  Total Child-Pugh score of 5 or 6, inclusive (mild); or 7 to 9, inclusive (moderate);&#xD;
             or 10 to 15, inclusive (severe) as determined by the investigator&#xD;
&#xD;
          -  Stable hepatic function during screening and those measured on Day 1&#xD;
&#xD;
          -  Stable renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants with normal hepatic function&#xD;
&#xD;
          -  Hepatitis B surface antigen (HBsAg) or hepatitis C antibodies at screening&#xD;
             Participants with (Mild, Moderate or Severe) hepatic impairment&#xD;
&#xD;
          -  Severe ascites or pleural effusion; prothrombin time greater than (&gt;)18 seconds;&#xD;
             evidence of progressive liver disease within the previous 4 weeks, as indicated by&#xD;
             changes in hepatic transaminases, alkaline phosphatase, and gamma-glutamyl transferase&#xD;
&#xD;
          -  History of hepatopulmonary syndrome, hydrothorax, or significant hepatorenal syndrome&#xD;
&#xD;
          -  Acute or exacerbating hepatitis, fluctuating or rapidly deteriorating hepatic function&#xD;
             as indicated by widely varying or worsening of clinical and/or laboratory signs of&#xD;
             hepatic impairment in the judgment of either the investigator or the sponsor's medical&#xD;
             monitor&#xD;
&#xD;
          -  Clinically significant laboratory findings except as related to hepatic impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CRS Clinical Research Services Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>APEX GmbH</name>
      <address>
        <city>Munchen</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108929</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency.&#xD;
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

